Nisa Investment Advisors LLC Invests $237,000 in 10x Genomics, Inc. (NASDAQ:TXG)

Nisa Investment Advisors LLC acquired a new stake in shares of 10x Genomics, Inc. (NASDAQ:TXG) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 16,500 shares of the company’s stock, valued at approximately $237,000.

Other large investors also recently bought and sold shares of the company. GAMMA Investing LLC raised its stake in shares of 10x Genomics by 451.8% during the third quarter. GAMMA Investing LLC now owns 1,545 shares of the company’s stock valued at $35,000 after acquiring an additional 1,265 shares in the last quarter. Capital Performance Advisors LLP bought a new stake in 10x Genomics during the 3rd quarter valued at $35,000. Blue Trust Inc. lifted its holdings in shares of 10x Genomics by 136.5% in the 3rd quarter. Blue Trust Inc. now owns 1,776 shares of the company’s stock worth $40,000 after buying an additional 1,025 shares during the period. Sound Income Strategies LLC purchased a new position in 10x Genomics during the 3rd quarter valued at about $46,000. Finally, Venturi Wealth Management LLC raised its holdings in shares of 10x Genomics by 1,108.9% in the 3rd quarter. Venturi Wealth Management LLC now owns 2,442 shares of the company’s stock valued at $55,000 after purchasing an additional 2,240 shares in the last quarter. Hedge funds and other institutional investors own 84.68% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on TXG shares. Citigroup decreased their price objective on 10x Genomics from $35.00 to $23.00 and set a “buy” rating for the company in a research note on Wednesday, October 30th. Morgan Stanley reduced their price target on 10x Genomics from $30.00 to $28.00 and set an “overweight” rating on the stock in a research report on Monday, January 13th. Canaccord Genuity Group lowered their price objective on 10x Genomics from $32.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, October 10th. Barclays reduced their target price on 10x Genomics from $21.00 to $19.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of 10x Genomics in a report on Saturday, January 18th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $23.86.

10x Genomics Stock Performance

TXG stock opened at $14.84 on Thursday. 10x Genomics, Inc. has a 12-month low of $12.95 and a 12-month high of $51.22. The business’s 50-day moving average is $15.11 and its 200 day moving average is $17.80. The stock has a market cap of $1.80 billion, a price-to-earnings ratio of -9.70 and a beta of 1.83.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings results on Tuesday, October 29th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.04. The firm had revenue of $151.65 million for the quarter, compared to analyst estimates of $158.84 million. 10x Genomics had a negative return on equity of 25.07% and a negative net margin of 28.93%. The business’s revenue was down 1.3% on a year-over-year basis. During the same period in the previous year, the company posted ($0.51) earnings per share. As a group, equities analysts forecast that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.